Somewhere it was noted that the US FDA had stipulated that the...

Somewhere it was noted that the US FDA had stipulated that the Xanamen trial be at the 10mg dose level. ACW sought to have a higher dose level, but had to go with the lower dose to get the trial approved in the US. My understanding was that as soon as possible they had desired to put in place trials at a higher dose level, which is currently underway. It would appear the DSMB reviews have been handy in enabling this higher dose trial to go ahead.

It is good to raise these questions as there would be numerous potential investors who haven't seen the whole story. Cheers DYOR